Learning from Case Law: Mylan IRE Healthcare v European Commission (Case C-237/22) concerning orphan medicinal products

Last updated: 10 January 2025 To view updates, click on the ‘+’ sign below. This post is an attempt to to provide information on Case C-237/22 concerning Mylan IRE Healthcare v European Commission, including clarification of the concepts of “Significant…

Read MoreLearning from Case Law: Mylan IRE Healthcare v European Commission (Case C-237/22) concerning orphan medicinal products

Learning from Case Law: Opinion and judgement on Cases C-119/22 (MSD vs Teva) and C-149/22 (MSD vs Clonmel) on conditions under which SPCs may be granted for combination products in the EU

Last updated: 3 January 2025 To view updates, click on the ‘+’ below: This post is an attempt to to provide information on recent progress concerning two cases, one from the Finnish Market Court C-119/22 (Teva v MSD) and the…

Read MoreLearning from Case Law: Opinion and judgement on Cases C-119/22 (MSD vs Teva) and C-149/22 (MSD vs Clonmel) on conditions under which SPCs may be granted for combination products in the EU

MHRA to relaunch the Innovative Licensing and Access Pathway (ILAP) pathway in Q1 2025

Last updated: 9 April 2025 To view updates, click on the ‘+’ sign below: The ILAP first launched in January 2021 to offer an integrated pre-market pathway awarding an Innovation Passport for promising medicines across England, Scotland and Wales. The…

Read MoreMHRA to relaunch the Innovative Licensing and Access Pathway (ILAP) pathway in Q1 2025